Clene therapies. Clean results.

Clene offers a new approach to drug development and a new hope for many patients with unmet medical needs. Bringing the science of nanomedicine to patients is our commitment: Clean-Surface Nanosuspensions™ for Clene therapies and clean results.


Rob Etherington

Rob Etherington


Rob Etherington has held a variety of roles over his 20+ years in the pharmaceutical industry. Rob is the former senior vice president in charge of commercial operations at Actelion Pharmaceuticals US, Inc, which he joined in its founding year of commercialization as its first marketing officer. During his 13-year tenure at Actelion, Rob presided over the commercialization activities as Actelion grew into a $7+ billion market-cap company with annual sales of nearly $2 billion across a portfolio of 4 approved drugs, including Tracleer (2000-2013). Rob also served as an officer of Actelion Pharmaceuticals US, Inc, and on the US Executive Board. Before joining Actelion, Rob served as a marketing leader at Pfizer (Parke-Davis Division, Warner-Lambert Company) with key responsibilities in the launch years for Lipitor and Rezulin. Rob is an alumnus of the Harvard Business School General Management Program, and he holds an MBA from the Marriott School at Brigham Young University.

William Houghton

Glen S. Frick, MD, PhD

Chief Medical Officer

Glen S. Frick, MD, PhD is an NIH Fellowship-Trained Pharmacologist and Board-Certified Pediatrician with over fifteen years of extensive Phase 1-4 clinical trial experience. Glen has held key roles within the pharmaceutical industry, including GlaxoSmithKline, Wyeth/Pfizer, Shire and Endo. He has conducted clinical and translational medicine studies in Neurodegeneration, Respiratory, Inflammation, Psychiatry, Pain and Dermatology. Glen completed an MD/PhD program at SUNY-Downstate Medical Center obtaining his PhD in Developmental Neural & Behavioral Science. He served as Global Development Team Leader for the Vyvanse ADHD franchise during his five years at Shire and most recently comes from Endo where he was VP of Clinical Development overseeing all clinical development programs for Belbuca, Opana and Xiaflex. 

Mark Mortenson

Mark Mortenson

Co-Founder and Chief Technology Officer

Mark Mortenson is a co-inventor of the Clean-Surface Nanosuspension™ technology platform, as well as the inventor/co-inventor on 17 other US patents and hundreds of corresponding foreign patents. Mark is a former chief patent counsel responsible for approximately 5500 patents and patent applications in the United States and 44 foreign countries, and is the former chief operating officer of research, development, and manufacturing for an advanced materials-based company of over 300 employees. Mark holds a BS in physics and a BS in ceramic engineering from Alfred University, an MS in material science from Pennsylvania State University, and a JD from George Washington University.